Science Hub is Novo Nordisk’s one-stop portal for all our scientific publications and clinical trials, congress materials and medical updates. Sign up to gain full access.
UBT251, a triple GLP-1, GIP, and GCG receptor agonist in patients with type 2 diabetes: a multicenter, double-blind, placebo- and active-controlled, randomised, phase II trial
Authors:
Gang Fang1; Caroline Swift1; Josh Noone1; Yuanjie Liang1; Sherif Mehanna1; Thomas P. Gunnarsson2; Kathryn Tierney3